Novo Nordisk A/S (NYSE:NVO) Shares Sold by GPS Wealth Strategies Group LLC

GPS Wealth Strategies Group LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 14.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,838 shares of the company’s stock after selling 947 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in Novo Nordisk A/S were worth $502,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Novare Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after acquiring an additional 85 shares during the last quarter. Rosenberg Matthew Hamilton increased its stake in Novo Nordisk A/S by 2.5% in the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after purchasing an additional 94 shares during the last quarter. Spinnaker Trust raised its holdings in Novo Nordisk A/S by 1.1% during the third quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock worth $1,145,000 after purchasing an additional 100 shares in the last quarter. Marco Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 1.5% during the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after buying an additional 100 shares during the last quarter. Finally, Carr Financial Group Corp boosted its holdings in shares of Novo Nordisk A/S by 5.1% in the 3rd quarter. Carr Financial Group Corp now owns 2,100 shares of the company’s stock valued at $250,000 after buying an additional 101 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $84.36 on Monday. The stock’s 50-day moving average price is $93.56 and its 200 day moving average price is $113.03. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $378.56 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.